Drug Trial Radar · NCT06669247
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
186
Planned (sponsor's estimate)
Start
Dec 11, 2024
Primary completion
Nov 11, 2033
Study completion Nov 1, 2035
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Nov 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a "study drug" or "study drugs" when combined). This study is the first time REGN7945 will be tested in humans. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after several other therapies had failed. The aim of the study is to see how safe, tolerable, and effective REGN7945 is when given in combination with linvoseltamab, compared with linvoseltamab alone. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug(s) * How many people treated with REGN7945 and linvoseltamab compared to linvoseltamab alone have improvement of their multiple myeloma and by how much * How long people benefit from receiving REGN7945 in combination with linvoseltamab compared with linvoseltamab alone * How much study drug(s) is in the blood at different times * Whether the body makes antibodies against the study drugs(s) (which could make the study drug(s) less effective or could lead to side effects) * If there is any change in pain and cancer-related symptoms, how well people are able to function, and their quality of life when taking the study drug(s)
Conditions
- Relapsed/Refractory Multiple Myeloma
Interventions
LinvoseltamabDrug
Administered per protocol
REGN7945+LinvoseltamabDrug
Administered per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (DLTs) from the first dose of REGN7945 in combination with linvoseltamabTime frame: Up to 21 days
- Incidence of treatment emergent adverse events (TEAEs) during the treatment period with REGN7945 in combination with linvoseltamabTime frame: Up to 5 years
- Severity of TEAEs during the treatment period with REGN7945 in combination with linvoseltamabTime frame: Up to 5 years
- Very Good Partial Response (VGPR) or better as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria in patients receiving combination therapyTime frame: Within 12 weeks of starting cycle 1
- VGPR or better as determined by the investigator using the IMWG response criteria in patients receiving linvoseltamab monotherapyTime frame: Within 12 weeks of starting cycle 1
- Partial Response (PR) or better as determined by the investigator using the IMWG response criteria in patients receiving combination therapyTime frame: Within 12 weeks of starting cycle 1
- PR or better as determined by the investigator using the IMWG response criteria in patients receiving linvoseltamab monotherapyTime frame: Within 12 weeks of starting cycle 1
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia · Recruiting
Illawarra Cancer Care Centre
Wollongong, New South Wales, Australia · Recruiting
Pindara Private Hospital
Benowa, Queensland, Australia · Recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Recruiting
Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
St Vincents Hospital Melbourne
Melbourne, Victoria, Australia · Recruiting
University College London Hospitals
London, United Kingdom · Recruiting
St Thomas Hospital
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.